MDMA for Borderline Personality Disorder

(MDMA in BPD Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Sarah K Fineberg, MD, PhD

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Yale University

No Placebo Group

Prior Safety Data

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

The purpose of this study is to test the effects of MDMA (3,4-methylenedioxymethamphetamine) on social cognition in adults with Borderline Personality Disorder.

Research Team

Sarah K Fineberg, MD, PhD

Principal Investigator

Yale University

Eligibility Criteria

This trial is for adults with Borderline Personality Disorder. Specific eligibility criteria are not provided, but typically participants must meet diagnostic criteria for the condition being studied and may need to pass certain health checks.

Inclusion Criteria

Willing to remain overnight at the study site after each experimental session if recommended

Able to provide written informed consent according to Yale IRB guidelines

Able to read and write English proficiently

Exclusion Criteria

History of bipolar disorder, schizophrenia, schizoaffective disorder, or currently exhibiting psychotic features

My heart often beats faster than 90 beats per minute.

I have a history of serious medical or neurological illness.

Treatment Details

Interventions

• MDMA (Other)

Trial Overview The study is testing the effects of MDMA on social cognition in individuals with Borderline Personality Disorder. Social cognition involves how people process, store, and apply information about others and social situations.

Participant Groups

Group I: Open-Label MDMA Experimental Treatment 1 Intervention

Participants will receive one dose of open-label 3,4-methylenedioxymethamphetamine (MDMA).

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

Nancy J. Brown

Yale University

Chief Medical Officer since 2020

MD from Yale School of Medicine

Peter Salovey

Yale University

Chief Executive Officer since 2013

PhD in Psychology from Yale University

Connecticut Mental Health Center

Collaborator

Trials

2

Recruited

160+